| 000 | 01841 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515013603.0 | ||
| 264 | 0 | _c20060323 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a0066-4804 | ||
| 024 | 7 |
_a10.1128/AAC.50.2.667-673.2006 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStocker, Hartmut | |
| 245 | 0 | 0 |
_aPharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cFeb 2006 |
||
| 300 |
_a667-73 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aEnfuvirtide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHIV Envelope Protein gp41 |
| 650 | 0 | 4 |
_aHIV Fusion Inhibitors _xpharmacokinetics |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPeptide Fragments _xpharmacokinetics |
| 650 | 0 | 4 | _aReference Values |
| 700 | 1 | _aKloft, Charlotte | |
| 700 | 1 | _aPlock, Nele | |
| 700 | 1 | _aBreske, Antje | |
| 700 | 1 | _aKruse, Guido | |
| 700 | 1 | _aHerzmann, Christian | |
| 700 | 1 | _aSchulbin, Hubert | |
| 700 | 1 | _aKreckel, Peter | |
| 700 | 1 | _aWeber, Christoph | |
| 700 | 1 | _aGoebel, Frank | |
| 700 | 1 | _aRoeling, Joerg | |
| 700 | 1 | _aStaszewski, Schlomo | |
| 700 | 1 | _aPlettenberg, Andreas | |
| 700 | 1 | _aMoecklinghoff, Christiane | |
| 700 | 1 | _aArastéh, Keikawus | |
| 700 | 1 | _aKurowski, Michael | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 50 _gno. 2 _gp. 667-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.50.2.667-673.2006 _zAvailable from publisher's website |
| 999 |
_c16051334 _d16051334 |
||